Cardinal Health Inc
Cardinal Health Inc is a provider of health products and services, including the distribution of pharmaceutical and medical products.
Price history of Cardinal Health Inc
Price history of Cardinal Health Inc
Performance & Momentum
Wells Fargo Raises Price Target for Cardinal Health
Wells Fargo has increased its price target for Cardinal Health (NYSE: CAH) from $237 to $256, maintaining an 'Overweight' rating. This move follows strong Q2 results, highlighting the company's overall robust health. This positive update may support the stock's favorable performance in the short to medium term on the NYSE.
Strategic Analysis
Cardinal Health Inc • 2026
Cardinal Health is a key U.S. player in the healthcare value chain, focused on pharmaceutical distribution and medical devices. Its business model is based on high volumes, critical logistics, and deep integration into the flows of hospitals, pharmacies, and care providers, making it a strategic intermediary rather than a pure manufacturer.
- Essential distributor position in a defensive, structurally resilient industry
- Diversification across drugs, medical devices, and healthcare services, reducing reliance on any single business line
- Ability to benefit from scale effects and the logistics complexity of the sector, creating barriers to entry
- Margins are generally under pressure in distribution, with reliance on operational discipline
- Exposure to intense competition and limited bargaining power versus major suppliers and customers
Momentum is solid and reflects a well-established upward trend across multiple time horizons, despite a more hesitant recent move in the short term. Strategically, this suggests a stock supported by the quality of its defensive business model and by market confidence in its ability to generate value consistently rather than through spectacular growth.
Similar stocks to Cardinal Health Inc
Recent News
Cardinal Health Inc
Citi Upgrades Cardinal Health with $244 Price Target
4 months agoCardinal Health (CAH) shares rise following Citi's upgrade from 'Neutral' to 'Buy' and price target increase from $190 to $244. The positive outlook highlights CAH as a defensive pick amid recession concerns. The stock recently hit a 52-week high, underscoring investor confidence in its strong fundamentals and medium-term prospects.
Cardinal Health Hits Annual High on Strong Q3 Results
7 months agoCardinal Health (NYSE: CAH) reported third-quarter 2025 results that exceeded expectations, with revenue rising 22.4% to $64.01 billion and non-GAAP EPS of $2.55, beating analyst consensus by 17.3%. Buoyed by this performance, the company raised its full-year 2026 guidance, driving the stock to a new 52-week high. Additionally, the stock's fair value estimate was revised upward, reflecting growing analyst optimism about Cardinal Health's growth prospects.
Take control
of your investments
Track your portfolios, analyze your performance and receive personalized insights to invest with strategy.
- Real-time multi-portfolio tracking
- AI analysis of your positions
- Counter your cognitive biases
